These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Supersensitization of the oral response to SKF 38393 in neonatal 6-hydroxydopamine-lesioned rats is eliminated by neonatal 5,7-dihydroxytryptamine treatment. Brus R; Kostrzewa RM; Perry KW; Fuller RW J Pharmacol Exp Ther; 1994 Jan; 268(1):231-7. PubMed ID: 8301563 [TBL] [Abstract][Full Text] [Related]
3. Interactive modulation by dopamine and serotonin neurons of receptor sensitivity of the alternate neurochemical system. Kostrzewa RM; Brus R; Perry KW Pol J Pharmacol; 1999; 51(1):39-47. PubMed ID: 10389143 [TBL] [Abstract][Full Text] [Related]
4. Ontogenetic quinpirole treatments fail to prime for D2 agonist-enhancement of locomotor activity in 6-hydroxydopamine-lesioned rats. Brus R; Kostrzewa RM; Nowak P; Perry KW; Kostrzewa JP Neurotox Res; 2003; 5(5):329-38. PubMed ID: 14715452 [TBL] [Abstract][Full Text] [Related]
5. Proposed animal model of attention deficit hyperactivity disorder. Kostrzewa RM; Brus R; Kalbfleisch JH; Perry KW; Fuller RW Brain Res Bull; 1994; 34(2):161-7. PubMed ID: 7913871 [TBL] [Abstract][Full Text] [Related]
6. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding. Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767 [TBL] [Abstract][Full Text] [Related]
7. Supersensitized D1 receptors mediate enhanced oral activity after neonatal 6-OHDA. Kostrzewa RM; Gong L Pharmacol Biochem Behav; 1991 Jul; 39(3):677-82. PubMed ID: 1686103 [TBL] [Abstract][Full Text] [Related]
8. p-Chloroamphetamine-Enhanced Neostriatal Dopamine Exocytosis in Rats Neonatally Co-lesioned with 6-OHDA and 5,7-DHT: Relevance to Parkinson's Disease. Kostrzewa JP; Kostrzewa RM Neurotox Res; 2020 Mar; 37(3):543-552. PubMed ID: 31939043 [TBL] [Abstract][Full Text] [Related]
9. Behavioral responsitivity to dopamine receptor agonists after extensive striatal dopamine lesions during development. Neal-Beliveau BS; Joyce JN Dev Psychobiol; 1998 May; 32(4):313-26. PubMed ID: 9589220 [TBL] [Abstract][Full Text] [Related]
10. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation. Hu XT; White FJ Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677 [TBL] [Abstract][Full Text] [Related]
18. Supersensitization of the oral response to SKF 38393 in neonatal 6-OHDA-lesioned rats is mediated through a serotonin system. Gong L; Kostrzewa RM; Fuller RW; Perry KW J Pharmacol Exp Ther; 1992 Jun; 261(3):1000-7. PubMed ID: 1602367 [TBL] [Abstract][Full Text] [Related]
19. Persistent spontaneous oral dyskinesias in haloperidol-withdrawn rats neonatally lesioned with 6-hydroxydopamine: absence of an association with the Bmax for [3H]raclopride binding to neostriatal homogenates. Huang NY; Kostrzewa RM; Li C; Perry KW; Fuller RW J Pharmacol Exp Ther; 1997 Jan; 280(1):268-76. PubMed ID: 8996206 [TBL] [Abstract][Full Text] [Related]
20. Dose-related effects of a neonatal 6-OHDA lesion on SKF 38393- and m-chlorophenylpiperazine-induced oral activity responses of rats. Gong L; Kostrzewa RM; Perry KW; Fuller RW Brain Res Dev Brain Res; 1993 Dec; 76(2):233-8. PubMed ID: 8149589 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]